The primary Phase 1 purpose of this study is to assess overall safety and tolerability and recommended Phase 2 dose (RP2D) of APL-101-01 (SPARTA).
The Phase 2 portion will assess the efficacy of the dose determined in Phase 1 in individuals with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
General Information
Sponsor:
Apollomics Inc.
Trial Name:
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Trial Number:
APL-101-01 (Vebreltinib, formerly Bozitinib)
ClinicalTrials.gov Identifier:
NCT03175224
Recruitment Status:
Recruiting
First Posted:
June 5, 2017
Last Update Posted:
October 30, 2020
Website:
https://www.spartacancertrial.com/